Responsibility： 1.Oversee the development and implementation of HPLC/UPLC based methods in support of protein, mRNA product analysis, including method development, qualification/validation, troubleshooting, transfer to QC lab and collaboration with partner organizations. 2.Demonstrate strong technical capabilities in multiple analytical techniques 3.Lead and manage a small group of junior scientists. Supervise/mentor junior group members on daily laboratory work, experimental design, data interpretation and troubleshooting. Train and manage new group members on basic analytical lab skills and company compliance. 4.Proactively communicate and collaborate with cross-functional team members in technique, project goals and results discussion. 5.Draft and review of relevant CMC sections that support regulatory filings including INDs and BLAs. 6.Draft method related documents: Draft analytical method procedure, method development report, method qualification protocol and report, method transfer protocol, etc. 7.Maintain necessary documentation in accordance with company SOPs and GMP guidelines Qualifications: 1.Ph.D. or M.S. in analytical chemistry, biochemistry or related scientific discipline, 0-5 years (Ph.D) or 4-8 years (M.S) relevant experience is required. 2.Extensive hands-on experiences in HPLC/UPLC technologies, including industrial experiences in the development and validation of HPLC and LC-MS method for CMC supporting. 3.Experience in biochemical and physicochemical characterization of therapeutics protein or other biological product portfolio. 4.Proven technical writing skills demonstrated by peer-reviewed publications in professional journals. 5.Excellent communication skills (both verbal and written) and interpersonal skills. Fluent in English and Chinese. Self-motivated and organized. 6.In-depth knowledge of GMPs and experience in interacting with health authorities (FDA, EMA, CED etc.) are advantageous. 7.Experiences in analytical method development, validation and transfer for complex biomolecules (fusion protein, ADC, LNP) or late-stage biopharmaceutical projects are prefer********************